Cancer Cell Line & PDX Services

Cancer cell lines or patient derived xenograft (PDX) models are commonly engrafted and screened in mouse models of cancer such as NSG mice, nude mice, and SCID mice. However, rats may provide certain advantages as a cancer xenograft model, such as larger tissue/blood samples and typically more translational compound PK properties. Unfortunately, a lack in severely immunodeficient rat models has limited their use, until now. For example, the athymic Nude rat or RNU rat is only partially immunodeficient lacking T-cells. In order to overcome the limitations of current immunodeficient rat and mouse models, Hera has introduced a Rag2/Il2rg double knockout SCID rat, the OncoRat SRG, which are more immunodeficient than Nude rats and amenable as tumor models and for humanization. Hera provides the OncoRat SRG to researchers off-the-shelf as well as tumor xenograft studies conducted at Hera.

Efficacy Study Services

  • The OncoRat SRG, a Rag2/Il2rg double knockout, has been established as a valuable xenograft model for preclinical oncology and humanized immune system model for preclinical immuno-oncology.
  • OncoRat SRG pre-implanted with tumor models
  • PDX model creation and validation
  • Gene editing (reporters cell lines for in-vivo imaging or disease models)
SRG Update Sign Up
AACR Poster on Xenografts
AACR Poster on Humanization
AACR Poster on PDX models
OncoRat SRG slide deck
Request Proposal

PDX-derived cell line grows ~10x bigger in OncoRat SRG vs NSG mouse

When a cell line derived from an ovarian PDX model was transplanted SQ the take rate was 100% in both species but the tumor ten-fold bigger in the OncoRat SRG compared with the NSG mouse, in the same amount of time. The OncoRat SRG thus provides the possibility of getting adequate sample size from PDX tissue for an efficacy study faster than mouse. Download AACR Poster on PDX Models for more data.

VCaP tumor growth in OncoRat SRG

VCaP prostate cancer cells known to have poor engraftment rates and kinetics in immunodeficient mice (i.e. nude mice, SCID mice, NSG mice), thrived in the OncoRat SRG. Preclinical studies with Enzalutamide against the VCaP tumor performed as expected. Download AACR Poster on Humanization.

Humanized mice engrafted with components of the human immune system enable preclinical animal studies for therapeutic immune modulation, tumor-immune system interactions and tumor immune escape. Humanized mice are often desired over or complement syngeneic mouse models which use the mouse immune system. Hera has demonstrated capabilities in humanized NOD SCID mouse and OncoRat SRG for preclinical oncology services. All of Hera’s cancer cell line and PDX model services can be conducted in immunodeficient mice or rats as well as humanized mice or rats. Please see our Immuno-oncology in Humanized Rodents page for demonstration data and information.

Xenograft Cell Lines and PDX

Efficacy studies can be conducted with xenograft cell lines or patient derived tumor xenograft samples either chosen from commercially available options or client provided cells.

Customized Study Design

Almost all details of the efficacy study can be customized to meet your needs. From the length and size of the study, the animal model used as well as special and unique requests. Our team of expert scientists can help design and implement the ideal study for you.

In additional to flexible study design, additional measurements and data can be added to your study, including histology, ophthalmology, toxicokinetic, necropsy, histopathology, and clinical pathology and more.

Request A Quote
Basic Study Outline
Model Species:OncoRat SRG (SD-Rag2-Il2rg KO)
NSG mice, Nude mice, SCID mice, NOG mice, NCG mice, humanized mice or OncoRat SRG etc.
Length:28 days
Study Design:3 test article treated groups,  low dose, mid dose and high dose,  and 2 controls. 5 males and 5 females for each group.
Dosing Method:Oral gavage, daily
Tumor Implantation:Subcutaneous (subQ) or orthotopic mouse model or rat model
Observations:Tumor size, bodyweight, food consumption, and clinical observations.
Reporting:Raw Data, Draft, and Final Report